TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34166627

Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg (bodyweight ≥50 kg) or 400 mg (bodyweight <50 kg) once daily until disease progression or intolerable toxicity.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Savolitinib
Number of subjects: 70
Study: 34166741

Group type: EXPERIMENTAL
Intervention: Prolonged targeted temperature management (TTM) at 33 °C for 48 h
Number of subjects: 352

Group type: COMPARATOR
Intervention: Standard targeted temperature management (TTM) for 24-h
Number of subjects: 352
Study: 34166998

Group type: EXPERIMENTAL
Intervention: Higher plerixafor dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 0
Study: 34167520

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM+)
Number of subjects: 3014

Group type: COMPARATOR
Intervention: No Diabetes Mellitus (DM-)
Number of subjects: 3014
Study: 34167531

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass, one anastomosis gastric bypass)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 142
Study: 34167539

Group type: EXPERIMENTAL
Intervention: TyG index increase (1-SD increase of 0.58)
Number of subjects: 12320

Group type: EXPERIMENTAL
Intervention: TyG index quartiles (comparing extreme quartiles)
Number of subjects: 12320

Group type: EXPERIMENTAL
Intervention: TyG index trajectory at high level
Number of subjects: 12320

Group type: EXPERIMENTAL
Intervention: TyG index trajectory at very high level
Number of subjects: 12320
Study: 34167584

Group type: EXPERIMENTAL
Intervention: Back to Living Well program (Physical activity + Education + Self-management)
Number of subjects: 17
Study: 34167689

Group type: EXPERIMENTAL
Intervention: Frequent supraventricular ectopic complexes
Number of subjects: 6100

Group type: EXPERIMENTAL
Intervention: Irregular supraventricular tachycardias
Number of subjects: 6100

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 6100
Study: 34168015

Group type: EXPERIMENTAL
Intervention: sequential α-/β-emitter therapy
Number of subjects: 0
Study: 34168021

Group type: EXPERIMENTAL
Intervention: Cognitive assessments including a novel cognitive composite, the Global Preclinical Alzheimer's Cognitive Composite, brain MRI, positron emission tomography, and cerebrospinal fluid analysis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle, cognitive and functional data, and biosamples (blood, urine, and saliva) collection.
Number of subjects: 0
Study: 34168024

Group type: EXPERIMENTAL
Intervention: Screen time (television+DVD viewing)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Screen time (general)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control (no screen time)
Number of subjects: 558
Study: 34168437

Group type: EXPERIMENTAL
Intervention: Silent Myocardial Infarction (SMI)
Number of subjects: 4953

Group type: EXPERIMENTAL
Intervention: Clinical Myocardial Infarction (CMI)
Number of subjects: 4953

Group type: COMPARATOR
Intervention: No Myocardial Infarction (MI)
Number of subjects: 4953
Study: 34168480

Group type: EXPERIMENTAL
Intervention: First-generation EGFR-TKIs combined with chemotherapy
Number of subjects: 21
Study: 34168545

Group type: EXPERIMENTAL
Intervention: Directional DBS electrodes implanted in the cuneiform nucleus (CnF)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: DTI-based targeting and intraoperative stimulation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Directional DBS in the cuneiform nucleus (CnF)
Number of subjects: 1
Study: 34168611

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34168987

Group type: EXPERIMENTAL
Intervention: Pomalidomide (POM) 2.6 mg/m²
Number of subjects: 46
Study: 34169045

Group type: EXPERIMENTAL
Intervention: Walnuts, specific dosage and duration not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-Chain Polyunsaturated Fatty Acids, specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34169063

Group type: EXPERIMENTAL
Intervention: Foot-core exercise intervention program
Number of subjects: 85
Study: 34169175

Group type: EXPERIMENTAL
Intervention: HEAT training and HEAT awareness application for supervisors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-HEAT training
Number of subjects: 0
Study: 34169176

Group type: EXPERIMENTAL
Intervention: Outcomes Forecasting System (OFS) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of OFS at a fourth pediatric weight management program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot clinical trial incorporating OFS
Number of subjects: 0
Study: 34169200

Group type: EXPERIMENTAL
Intervention: Ravulizumab administered every 8 weeks
Number of subjects: 58
Study: 34169203

Group type: EXPERIMENTAL
Intervention: High-dose PF-06730512 (intravenous) every 2 weeks for 12 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low-dose PF-06730512 (intravenous) every 2 weeks for 12 weeks
Number of subjects: 44
Study: 34169247

Group type: EXPERIMENTAL
Intervention: Liver biopsies from obese individuals
Number of subjects: 29

Group type: COMPARATOR
Intervention: Liver biopsies from lean individuals
Number of subjects: 29
Study: 34169830

Group type: EXPERIMENTAL
Intervention: STANDARD Q COVID-19 AG test
Number of subjects: 4811

Group type: COMPARATOR
Intervention: RT-PCR test
Number of subjects: 4811

Group type: EXPERIMENTAL
Intervention: AG test
Number of subjects: 4811
Study: 34170433

Group type: EXPERIMENTAL
Intervention: Financial incentives (FI)
Number of subjects: 54
Study: 34170745

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD)
Number of subjects: 39
Study: 34170839

Group type: EXPERIMENTAL
Intervention: Community-based Kangaroo Mother Care (KMC) package including KMC kit, information and counseling material, and community mobilization through KMC champions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard essential newborn care (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based KMC package.
Number of subjects: 0
Study: 34171139

Group type: EXPERIMENTAL
Intervention: Recovery from acute COVID-19 infection
Number of subjects: 172
Study: 34171267

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy
Number of subjects: 823
Study: 34171339

Group type: EXPERIMENTAL
Intervention: Genotoxic therapy (temozolomide - TMZ)
Number of subjects: 0
Study: 34171449

Group type: EXPERIMENTAL
Intervention: Distal radial access (DRA) for PCI
Number of subjects: 250
Study: 34171919

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at discharge
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: New P2Y12 inhibitor regimen
Number of subjects: 323

Group type: COMPARATOR
Intervention: Surgical revascularization
Number of subjects: 323
Study: 34172005

Group type: EXPERIMENTAL
Intervention: Contrast-associated acute kidney injury (CA-AKI)
Number of subjects: 11943

Group type: EXPERIMENTAL
Intervention: CA-AKI patients
Number of subjects: 11943
Study: 34172085

Group type: EXPERIMENTAL
Intervention: Blocked practice order of an upper limb robotic exergame
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Random practice order of an upper limb robotic exergame
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 34172287

Group type: EXPERIMENTAL
Intervention: HrHPV testing on self-collected first-void urine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HrHPV testing on self-collected first-void urine in women aged 30 years and older
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploratory cut-off (CN ≤ 33.86) for hrHPV testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cervical samples taken by a clinician
Number of subjects: 0
Study: 34172290

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 2894
Study: 34172397

Group type: EXPERIMENTAL
Intervention: Low-risk Köhne category
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Medium-risk Köhne category
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: High-risk Köhne category
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: BRAF mutations
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Early tumor shrinkage (ETS) of 30% or greater and higher depth of response (DpR)
Number of subjects: 436
Study: 34172595

Group type: EXPERIMENTAL
Intervention: 68Ga-pentixafor PET/CT
Number of subjects: 15

Group type: COMPARATOR
Intervention: 18F-FDG PET/CT
Number of subjects: 15
Study: 34172622

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) as adjunctive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total pancreatectomy with islet autotransplantation (TPIAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreatic quantitative sensory testing
Number of subjects: 0
Study: 34172636

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry (IC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Common prediction equations based on body mass (BM) or dual-energy X-ray absorptiometry fat-free mass (FFM)
Number of subjects: 20
Study: 34173135

Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW) intervention
Number of subjects: 667
Study: 34173178

Group type: EXPERIMENTAL
Intervention: Malnutrition group (CONUT score > 1)
Number of subjects: 3170

Group type: COMPARATOR
Intervention: Normal group (CONUT score 0-1)
Number of subjects: 3170
Study: 34173196

Group type: EXPERIMENTAL
Intervention: PCPs agreeing to disclose results
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Responding PCPs
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Feeling qualified to share results
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Post-disclosure surveys
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Educational materials provided by the study
Number of subjects: 501
Study: 34173341

Group type: EXPERIMENTAL
Intervention: EGFR T790M mutation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Third-generation EGFR-TKI treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Concomitant genetic alterations in patients with EGFR T790M mutation receiving third-generation EGFR-TKIs
Number of subjects: 37
Study: 34173778

Group type: EXPERIMENTAL
Intervention: Botulinum toxin intervention
Number of subjects: 9

Group type: COMPARATOR
Intervention: No intervention (before botulinum toxin)
Number of subjects: 9
Study: 34173811

Group type: EXPERIMENTAL
Intervention: Dalcetrapib (cholesterol ester transfer protein inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34173822

Group type: EXPERIMENTAL
Intervention: Neutrophil counts, markers of extracellular chromatin, and inflammation measured at the culprit site in STEMI patients.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: High neutrophil counts and dsDNA levels at the culprit site.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: High DNase activity at the culprit site.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: dsDNA levels in porcine myocardial infarction model.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Markers of neutrophil activation, extracellular chromatin, DNase activity and CMR measurements.
Number of subjects: 101
Study: 34173924

Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel and carboplatin (6 cycles)
Number of subjects: 127
Study: 34173969

Group type: EXPERIMENTAL
Intervention: UVA therapy for 20 min daily for 5 days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: UVA therapy
Number of subjects: 5
Study: 34174083

Group type: EXPERIMENTAL
Intervention: QuickDASH
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: SPADI
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: NDII
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: DASH
Number of subjects: 182
Study: 34174177

Group type: EXPERIMENTAL
Intervention: Molecularly specific positron emission tomography imaging agents targeting ACE2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular imaging of ACE2
Number of subjects: 0
Study: 34174204

Group type: EXPERIMENTAL
Intervention: Research biopsies
Number of subjects: 129
Study: 34174279

Group type: EXPERIMENTAL
Intervention: TLR4 antagonists
Number of subjects: 0
Study: 34174834

Group type: EXPERIMENTAL
Intervention: Implementation Support Team
Number of subjects: 0
Study: 34174903

Group type: EXPERIMENTAL
Intervention: Diaphragmatic Thickening Fraction (DTF) measured at baseline and at 1, 4, 12, 24, 48, 72, and 96 hours of NIV treatment.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Respiratory rate/DTF ratio measured at baseline and at 1, 4, 12, 24, 48, 72, and 96 hours of NIV treatment.
Number of subjects: 18
Study: 34174963

Group type: EXPERIMENTAL
Intervention: Percutaneous implantation of allogeneic bone-forming cells (ALLOB; Bone Therapeutics) into the fracture site.
Number of subjects: 22
Study: 34175021

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) infusion at a target dose of 0.75 × 10^6 cells/kg
Number of subjects: 113
Study: 34175041

Group type: EXPERIMENTAL
Intervention: Genome editing approaches (e.g., ZFNs, TALENs, CRISPR-Cas9, base and prime editing)
Number of subjects: 0
Study: 34175043

Group type: EXPERIMENTAL
Intervention: Adeno-associated virus-vectorized gene therapies (gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental therapies using somatic cell gene editing
Number of subjects: 0
Study: 34175347

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 1407
Study: 34175365

Group type: EXPERIMENTAL
Intervention: LEAF-4L6715 (liposomal nanocarrier encapsulating trans-crocetin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LEAF-4L6715
Number of subjects: 0
Study: 34175582

Group type: EXPERIMENTAL
Intervention: Intramuscular magnesium sulphate administered by community-based health workers (CHWs)
Number of subjects: 8790

Group type: EXPERIMENTAL
Intervention: Oral methyldopa administered by Community Health Extension Workers (CHEWs) and nurses
Number of subjects: 8790

Group type: EXPERIMENTAL
Intervention: Urgent referrals completed by CHWs
Number of subjects: 8790
Study: 34176004

Group type: EXPERIMENTAL
Intervention: Patient Global Health Assessment (PtGA)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Pain scores
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Physician Global Health Assessment (PhGA)
Number of subjects: 137
Study: 34176020

Group type: EXPERIMENTAL
Intervention: Electronic tool for QoL assessment in routine inpatient and outpatient care
Number of subjects: 56

Group type: COMPARATOR
Intervention: No regular discussion of QoL-profiles by physicians
Number of subjects: 56
Study: 34176021

Group type: EXPERIMENTAL
Intervention: Dose reduction or delay due to neuropathy (group 2)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Discontinuation due to neuropathy (group 3)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Completed treatment without alteration (group 1)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Clinician-assessed neuropathy severity at dose reduction or delay
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patient-reported neuropathy severity at cycle 4 for dose reduction or delay
Number of subjects: 350
Study: 34176281

Group type: EXPERIMENTAL
Intervention: Renin-Angiotensin-Aldosterone System characterization; specific intervention details not available.
Number of subjects: 0
Study: 34176286

Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure readings after zero minutes of rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated Office Blood Pressure readings after five minutes of rest
Number of subjects: 0
Study: 34176288

Group type: EXPERIMENTAL
Intervention: Blood pressure self-management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 34176681

Group type: EXPERIMENTAL
Intervention: MCED test
Number of subjects: 4077
Study: 34176743

Group type: EXPERIMENTAL
Intervention: Hemopatch™ application to the pancreatic stump
Number of subjects: 52
Study: 34176752

Group type: EXPERIMENTAL
Intervention: Geriatric 8 (G8) and modified Geriatric 8 (mG8) screening tools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QoL questionnaires (EORTC QLQ-C30 and ELD-14)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional measurements (30-s chair stand test and handgrip strength test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment adherence and overall survival
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frailty assessment (G8 ≤ 14, mG8 ≥ 6)
Number of subjects: 0
Study: 34177198

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CP) intervention consisting of combined techniques of passive prolonged slow expiration, rhinopharyngeal clearance and provoked cough
Number of subjects: 45

Group type: COMPARATOR
Intervention: No chest physiotherapy intervention (control)
Number of subjects: 45
Study: 34177511

Group type: EXPERIMENTAL
Intervention: Robotic exoskeleton rehabilitation (Ekso® GT)
Number of subjects: 36
Study: 34177581

Group type: EXPERIMENTAL
Intervention: Lithium Carbonate; dosage and duration not available
Number of subjects: 0
Study: 34177626

Group type: EXPERIMENTAL
Intervention: Nasal High Flow (NHF) at 25 L/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Expiratory Resistive Loading (ERL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Baseline (BL)
Number of subjects: 8
Study: 34178122

Group type: EXPERIMENTAL
Intervention: Subsequent chemotherapy (147 patients, 73.5%)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Subsequent endocrine therapy (53 patients, 26.5%)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Subsequent therapies after palbociclib
Number of subjects: 200
Study: 34178635

Group type: EXPERIMENTAL
Intervention: Three-dimensional transrectal ultrasound parameters
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Three-dimensional transrectal ultrasound model
Number of subjects: 101

Group type: COMPARATOR
Intervention: Total mesorectal excision
Number of subjects: 101

Group type: COMPARATOR
Intervention: Watch-and-wait
Number of subjects: 101
Study: 34178681

Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate (EGCG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 38
Study: 34179977

Group type: EXPERIMENTAL
Intervention: 800 mg of OZ439 combined with 450 mg of DSM265
Number of subjects: 0

Group type: COMPARATOR
Intervention: OZ439 and DSM265 alone (three trials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of OZ439 and DSM265 (one trial)
Number of subjects: 0
Study: 34180037

Group type: EXPERIMENTAL
Intervention: Idasanutlin (QD × 5)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Idasanutlin (QW × 3)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Idasanutlin (QD × 3)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Idasanutlin (all regimens)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Idasanutlin (QD dosing)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Idasanutlin
Number of subjects: 85
Study: 34180161

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 17418

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 17418

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 17418

Group type: EXPERIMENTAL
Intervention: Overall ADHD medications
Number of subjects: 17418
Study: 34180331

Group type: EXPERIMENTAL
Intervention: Carfilzomib, dexamethasone, and daratumumab (KdD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 0
Study: 34180691

Group type: EXPERIMENTAL
Intervention: Implicit expectations from therapist measured by lexical decision task
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Explicit expectations from therapist
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Therapist becoming an attachment figure
Number of subjects: 308
Study: 34181190

Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography (SWE)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Multiparametric score using maximal WSS and SWE texture analysis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Wall Shear Stress (WSS)
Number of subjects: 46
Study: 34181276

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2)
Number of subjects: 109
Study: 34181697

Group type: EXPERIMENTAL
Intervention: High levels of fecal IgA antibodies against Cryptosporidium Cp23 sporozoite protein at one year of life
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Repeat infections with Cryptosporidium
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Repeat infections
Number of subjects: 392
Study: 34181872

Group type: EXPERIMENTAL
Intervention: Antibody features towards VAR2CSA identified through machine learning techniques
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Machine learning techniques (elastic net-regularized logistic regression, partial least squares discriminant analysis)
Number of subjects: 77
Study: 34182032

Group type: EXPERIMENTAL
Intervention: Heparin-bonded stent grafts
Number of subjects: 103
Study: 34182226

Group type: EXPERIMENTAL
Intervention: Pembrolizumab consolidation post-autologous stem cell transplantation
Number of subjects: 0
Study: 34182931

Group type: EXPERIMENTAL
Intervention: 3-dimensional transesophageal echocardiography (3D-TEE)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 233
Study: 34183020

Group type: EXPERIMENTAL
Intervention: Regular use of omega-3 fatty acid supplements (n=856)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Regular use of cod liver oil (CLO) (n=173)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Non-users of omega-3 fatty acid supplements (n=348)
Number of subjects: 1002
Study: 34183258

Group type: EXPERIMENTAL
Intervention: Delivery of mesenchymal stem/stromal cells (MSCs) to human subjects with RAS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental regenerative approaches involving reparative cells or products
Number of subjects: 0
Study: 34183269

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide
Number of subjects: 331
Study: 34184246

Group type: EXPERIMENTAL
Intervention: Late night removal (between 10 pm to midnight)
Number of subjects: 12241

Group type: COMPARATOR
Intervention: Early morning removal (between 6 am to 7 am)
Number of subjects: 12241

Group type: EXPERIMENTAL
Intervention: Shorter durations of catheterisation
Number of subjects: 12241

Group type: EXPERIMENTAL
Intervention: Clamping catheters
Number of subjects: 12241

Group type: EXPERIMENTAL
Intervention: Prophylactic alpha blockers
Number of subjects: 12241